Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maribavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.41 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maribavir SCHEMBL13641210 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL4656419 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL4936315 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL13082009 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL13640277 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL7634149 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL7634766 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL18459197 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL18459376 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL7638886 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381214-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2023-11-30 | — | — | US | claimed |
| US-11684632-B2 | Maribavir isomers, compositions, methods of making and methods of using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-27 | — | — | US | claimed |
| US-20220372059-A1 | CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-(1 BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | SHIRE VIROPHARMA LLC | 2022-11-24 | — | — | US | claimed |
| US-11130777-B2 | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | claimed |
| US-20200360414-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2020-11-19 | — | — | US | claimed |
| US-20200054658-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2020-02-20 | — | — | US | claimed |
| US-10485813-B2 | Maribavir isomers, compositions, methods of making and methods of using | SHIRE VIROPHARMA INCORPORATED (US) | 2019-11-26 | — | — | US | claimed |
| US-20190352326-A1 | CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-(1-BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | SHIRE VIROPHARMA LLC | 2019-11-21 | — | — | US | claimed |
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | claimed |
| US-20170027974-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2017-02-02 | — | — | US | claimed |
| US-6482939-B1 | Form vi 5,6-dichloro-2-(isopropylamino)-1-(β-l-ribofuranosyl)-1h-bezimimidazole | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | claimed |
| US-6469160-B1 | 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H -BENZIMIDAZOLE (AKA 1263W94) OF GIVEN X-RAY DIFFRACTION PATTERN | SMITHKLINE BEECHAM CORPORATION | 2002-10-22 | — | — | US | claimed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | claimed |
| EP-1071693-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LIMITED (GB) | 2001-01-31 | — | — | EP | claimed |
| EP-1070078-A2 | FORM VI 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | GLAXO GROUP LIMITED (GB) | 2001-01-24 | — | — | EP | claimed |
| US-6077832-A | FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION | GLAXO WELLCOME INC. (US) | 2000-06-20 | — | — | US | claimed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | claimed |
| WO-1999051618-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LIMITED (GB) | 1999-10-14 | — | — | WO | claimed |
| WO-1999051617-A2 | FORM VI 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(β-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | GLAXO GROUP LIMITED (GB) | 1999-10-14 | — | — | WO | claimed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684632-B2 | Maribavir isomers, compositions, methods of making and methods of using | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20200360414-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20200054658-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20220372059-A1 | CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-(1 BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | CDK2, CCNB3, CCNI | HDAC6 924/4885SLC15A1 3978/4885HSPA5 550/4885 |
| US-11130777-B2 | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1-beta-L-ribofuranosyl)-1H-benzimidazole | CDK2, TYMP, CCNI | HDAC6 1004/4885SLC15A1 3898/4885HSPA5 472/4885 |
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885SLC15A1 2842/4885HSPA5 1294/4885 |
| US-20230381214-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20170027974-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-10485813-B2 | Maribavir isomers, compositions, methods of making and methods of using | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20190352326-A1 | CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-(1-BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE | CDK2, TYMP, CCNI | HDAC6 1004/4885SLC15A1 3898/4885HSPA5 472/4885 |
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | HDAC6 78/4885SLC15A1 3489/4885HSPA5 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.